EU
ACAD icon

Emory University’s Acadia Pharmaceuticals ACAD Stock Holding History

Emory University’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-90,188
Closed -$2.41M – 20
2019
Q2 		$2.41M Sell
90,188
-12,398
-12% -$317K 1.7% 19
2019
Q1 		$2.75M Sell
102,586
-20,029
-16% -$468K 1.94% 8
2018
Q4 		$1.98M Sell
122,615
-73,986
-38% -$1.44M 1.56% 22
2018
Q3 		$4.08M Buy
196,601
+52,476
+36% +$826K 2.67% 3
2018
Q2 		$2.2M Buy
144,125
+59,411
+70% +$1.06M 1.46% 31
2018
Q1 		$1.9M Buy
84,714
+16,956
+25% +$469K 1.36% 41
2017
Q4 		$2.04M Buy
67,758
+14,781
+28% +$473K 1.75% 11
2017
Q3 		$2M Sell
52,977
-3,946
-7% -$128K 1.58% 12
2017
Q2 		$1.59M Buy
56,923
+788
+1% +$23.5K 1.4% 30
2017
Q1 		$1.93M Sell
56,135
-19,986
-26% -$705K 1.82% 19
2016
Q4 		$2.19M Buy
+76,121
New +$2.01M 2.16% 5
2015
Q3 		$1.37M Buy
41,505
+2,094
+5% +$87.1K 3.82% 10
2015
Q2 		$1.65M Buy
39,411
+10,055
+34% +$389K 2.23% 7
2015
Q1 		$957K Buy
+29,356
New +$1.01M 1.81% 9
2014
Q1 		– Sell
-1,381
Closed -$34K – 5
2013
Q4 		$34K Hold
1,381
– – 0.02% 6
2013
Q3 		$38K Hold
1,381
– – 0.02% 5
2013
Q2 		$25K Buy
+1,381
New +$19K 0.01% 5

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Emory University's ACAD Position: Q3 2019 in Review

Emory University sold out of Acadia Pharmaceuticals (ACAD) in Q3 2019, closing a stake of 90,188 shares — an estimated $2.41M sold.

Emory University first reported a position in ACAD in Q2 2013 and held it in 17 quarters. The position peaked at $4.08M in Q3 2018. 231 funds tracked by Wall St. Rank hold ACAD as of Q3 2019.

  • Emory University reported no remaining Acadia Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Emory University sold 90,188 Acadia Pharmaceuticals shares in Q3 2019, an estimated $2.41M.
  • Emory University first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 17 quarters.
  • Emory University's Acadia Pharmaceuticals position peaked at $4.08M in Q3 2018.
  • 231 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2019.

Based on Emory University's 13F filing for Q3 2019, filed 14 Nov 2019.